Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus RICE in Relapsed/Refractory Aggressive B-cell Lymphomas
NCT02471911Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Weill Cornell Medicine. Primary endpoint: Maximum Tolerated Dosage at 24 months. Started Dec 2015; status: completed.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02471911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471911.